Pharmacoeconomic Guidelines Around The World
Country/Region: Baltic (Latvia, Lithuania, Estonia)

PE Guidelines
Baltic guideline for economic evaluation of pharmaceuticals (Pharmacoeconomic Analysis)(2002)
PDF in English
PE Guidelines Source:
Additional Information:
Information up to date as of
Wednesday, January 17, 2018
PE Guidelines Key Features:
Key Features: | |
Title and year of the document | Baltic guideline for economic evaluation of pharmaceuticals (Pharmacoeconomic Analysis)(2002) |
Affiliation of authors | Experts from health authorities of the Baltic countries |
Purpose of the document | Drug reimbursement and other state funding decisions |
Standard reporting format included | No |
Disclosure | Yes |
Target audience of funding/ author's interests | Pharmaceutical companies. Baltic states’ health authority |
Perspective | Mainly health care perspective. If relevant, societal |
Indication | Approved one(s) |
Target population | Yes |
Subgroup analysis | Yes |
Choice of comparator | Most commonly used alternative or practice. Be justified. |
Time horizon | To model a sufficient analysis period when trial data provide too short a time frame |
Assumptions required | Not stated |
Preferred analytical technique | Any one of CMA, CEA, CUA. Need justification. |
Costs to be included | Only direct health care costs. If relevant, include all costs outside healthcare system, presented separately. |
Source of costs | Adapt local cost. Be specified. |
Modeling | Yes, requires details |
Systematic review of evidences | Encourage meta-analysis |
Preference for effectiveness over efficacy | Prefer data from RCTs |
Preferred outcome measure | Change in the health state. Absolute risk difference calculated |
Preferred method to derive utility | EuroQol, Health Utility Index |
Equity issues stated | Not stated |
Discounting costs | Yes, 5% justify for other rates |
Discounting outcomes | Yes, 5% |
Sensitivity analysis-parameters and range | Main assumption variables, confidence interval |
Sensitivity analysis-methods | Details of the statistical tests performed |
Presenting results | C/E ratio, ICER, total annual cost and benefit |
Incremental analysis | Yes |
Total costs vs effectiveness (cost/effectiveness ratio) | Yes |
Portability of results (Generalizability) | Adjustment needed |
Financial impact analysis | No |
Mandatory or recommended or voluntary |
Acknowledgement: Eglė Urbonavičiūtė, Chief specialist, deputizing for the Head of Medical Technology Division, State Health Care Accreditation Agency (VASPVT), Vilnius, Lithuania and Diāna Arāja, Head, Pharmacy Division, Ministry of Health of the Republic of Latvia, Riga, Latvia